Pharmakogenomik: Hype oder Hope?

M. Schwab; E. Schaeffeler; U. M. Zanger; H. Brauch; H. K. Kroemer

doi:10.1055/s-0031-1281691

TumorDiagnostik & Therapie, Table of Contents

TumorDiagnostik & Therapie 2011; 32: S70-S76
DOI: 10.1055/s-0031-1281691

Übersicht | Review article

Pharmakogenomik: Hype oder Hope?

Pharmacogenomics: Hype or Hope?M. Schwab¹ ^, ² , E. Schaeffeler¹ , U. M. Zanger¹ , H. Brauch¹ , H. K. Kroemer³

¹Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie
²Abteilung Klinische Pharmakologie, Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universitätsklinikum Tübingen
³Institut für Pharmakologie, Ernst-Moritz-Arndt Universität, Greifswald

Abstract

Full Text

References

Literatur

1 Altman R B, Kroemer H K, McCarty C A et al. Pharmacogenomics: will the promise be fulfilled?. Nat Rev Genet. 2011; 12 69-73
2 Ashley E A, Butte A J, Wheeler M T et al. Clinical assessment incorporating a personal genome. Lancet. 2010; 375 1525-1535
3 Biomarkers Definitions Working Group . Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001; 69 89-95
4 Brauch H, Mürdter T E, Eichelbaum M et al. Pharmacogenomics of Tamoxifen Therapy. Clin Chem. 2009; 55 1770-1782
5 Contopoulos-Ioannidis D G, Ntzani E, Ioannidis J P. Translation of highly promising basic science research into clinical applications. Am J Med. 2003; 114 477-484
6 Collins F S, McKusick V A. Implications of the Human Genome Project for medical science. J Am Med Assoc. 2001; 285 540-544
7 Evans W E, Hon Y Y, Bomgaars L et al. Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine. Clin Oncol. 2001; 19 2293-2301
8 FDA. Promoting Safe and Effective Genetic Testing in the United States. The Final Report of the Task Force on Genetic Testing. http://www.genome.gov/10001733 (last access date 4.1.2011)
9 Francke A L, Smit M C, Veer A J et al. Factors influencing the implementation of clinical guidelines for health care professionals: a systematic meta-review. BMC Med Inform Decis Mak. 2008; 8 38
10 Gage B F, Eby de C, Johnson J A et al. Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther. 2008; 84 326-331
11 Grol R, Grimshaw J. From best evidence to best practice: effective implementation of change in patients’ care. Lancet. 2003; 362 1225-1230
12 Guessous I, Gwinn M, Yu W et al. Trends in pharmacogenomic epidemiology: 2001-2007. Public Health Genomics. 2009; 12 142-148
13 Gurwitz D, Zika E, Hopkins M M et al. Pharmacogenetics in Europe: barriers and opportunities. Public Health Genomics. 2009; 12 134-141
14 Haddow J E, Palomaki G E. ACCE: a model process for evaluating data on emerging genetic tests. In: Khoury M J, Little J, Burke W, [Hrsg.] Human genome epidemiology.. Oxford: Oxford University Press; 2004: 217-233
15 Hartford C, Vasquez E, Schwab M et al. Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics. Cancer Res. 2007; 67 4965-4972
16 Heard E, Tishkoff S, Todd J A et al. Ten years of genetics and genomics: what have we achieved and where are we heading?. Nat Rev Genet. 2010; 11 723-733
17 Holmes M V, Shah T, Vickery C et al. Fulfilling the promise of personalized medicine?. PLoS One. 2009; 4 e7960
18 The G reat Beyond. Consumer genomics company snafu. 7.June.2010 http://blogs.nature.com/news/thegreatbeyond/2010/06/consumer_genomics_company_snaf_1.html (last access date 4.1.2011)
19 U.S. System of Oversight of Genetic Testing: A Response to the Charge of the Secretary of Health and Human Services Report of the Secretary’s Advisory Committee on Genetics, Health, and Society. http:// oba.od.nih.gov/oba/SACGHS/reports/SACGHS_oversight_report.pdf (last access date 4.1.2011)
20 SNPExpress .What is SNPExpress?. http://people.genome.duke.edu/˜dg48/ SNPExpress/index.php (last access date 4.1.2011)
21 International HapMap Project. http://snp.cshl.org/cgi-perl/gbrowse/ hapmap27_B36/ (last access date 4.1.2011)
22 Hughes A R, Spreen W R, Mosteller M et al. Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. Pharmacogenomics J. 2008; 8 365-374
23 Ikediobi O N, Shin J, Nussbaum R L et al. Addressing the challenges of the clinical application of pharmacogenetic testing. Clin Pharmacol Ther. 2009; 86 28-31
24 Klein T E, Altman R B. International Warfarin Pharmacogenetics Consortium . Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med. 2009; 360 753-764
25 Kerb R, Schwab M. Impact of pharmacogenetics on drug-drug interactions. In: Pang S K, Rodrigues D A, Peter R M, [Hrsg.] Enzymatic- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges.. New York: Springer; 2010: 51-74
26 Kirchheiner J, Schwab M. Heterogeneity of Drug Responses and Individualization of Therapy (Chapter 16). In: Waldman & Terzic (Hrsg) Pharmacology and Therapeutics.. Principles to Practice. Philadelphia: Elsevier; 2008: 225-238
27 Khoury M J, Feero W G, Reyes M et al. The genomic applications in practice and prevention network. Genet Med. 2009; 11 488-494
28 Khoury M J. Dealing with the evidence dilemma in genomics and personalized medicine. Clin Pharmacol Ther. 2010; 87 635-638
29 Little J, Higgins J P, Ioannidis J P et al. STrengthening the REporting of Genetic Association studies (STREGA): an extension of the STROBE Statement. Ann Intern Med. 2009; 150 206-215
30 Ng P C, Zhao Q, Levy S et al. Individual genomes instead of race for personalized medicine. Clin Pharmacol Ther. 2008; 84 306-309
31 Ng P C, Murray S S, Levy S et al. An agenda for personalized medicine. Nature. 2009; 461 724-726
32 Petitti D B, Teutsch S M, Barton M B et al. Update on the methods of the U.S. Preventive Services Task Force: insufficient evidence. Ann Intern Med. 2009; 150 199-205
33 Phillips E, Mallal S. Successful translation of pharmacogenetics into the clinic: the abacavir example. Mol Diagn Ther. 2009; 13 1-9
34 Rogowski W H, Grosse S D, Khoury M J. Challenges of translating genetic tests into clinical and public health practice. Nat Rev Genet. 2009; 10 489-495
35 Sawaya G F, Guirguis-Blake J, LeFevre M et al. Update on the methods of the U. S. Preventive Services Task Force: estimating certainty and magnitude of net benefit. Ann Intern Med. 2007; 147 871-875
36 Schaeffeler E, Stanulla M, Greil J et al. A novel TPMT missense mutation associated with TPMT deficiency in a five year old boy with ALL. Leukemia. 2003; 17 1422-1424
37 Schaeffeler E, Fischer C, Brockmeier D et al. Comprehensive analysis of thiopurine S-methyltransferase phenotype-genotype correlation in a large population of German-Caucasians and identification of novel TPMT variants. Pharmacogenetics. 2004; 14 407-417
38 Schaeffeler E, Zanger U M, Eichelbaum M et al. Highly multiplexed genotyping of thiopurine S-methyltransferase variants using MALDI-TOF mass spectrometry: reliable genotyping in different ethnic groups. Clin Chem. 2008; 54 1637-1647
39 Schroth W, Goetz M P, Hamann U et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. J Am Med Assoc. 2009; 302 1429-1436
40 Schwab M, Schaeffeler E, Marx C et al. Shortcoming in the diagnosis of thiopurine S-methyltransferase deficiency by using phenotyping. Gastroenterology. 2001; 121 500-501
41 Schwab M, Marx C, Zanger U M et al. Pharmakogenetik der Cytochrom P-450 Enzyme: Bedeutung für Wirkung und Nebenwirkung von Medikamenten. Dtsch Ärztebl. 2002; 99 A497-504
42 Stanulla M, Schaeffeler E, Möricke A et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukaemia on Berlin- Frankfurt-Münster protocols. Blood. 2009; 114 1314-1318
43 Teml A, Schaeffeler E, Herrlinger K R et al. Thiopurine treatment in inflammatory bowel disease: Clinical pharmacology and implication of pharmacogenetically-guided dosing. Clin Pharmacokinetics. 2007; 46 187-208
44 Teml A, Schaeffeler E, Schwab M. Pretreatment determination of TPMT – state of the art in clinical practice. Eur J Clin Pharmacol. 2009; 65 219-221
45 Wagner A K, Chan K A, Dashevsky I et al. FDA drug prescribing warnings: is the black box half empty or half full?. Pharmacoepidemiol Drug Saf. 2006; 15 369-386
46 Agency for Healthcare Research and Quality .U.S. Preventive Services Task Force (USPSTF). http://www.ahrq.gov/clinic/uspstfix.htm (last access date 4.1.2011)
47 Centers for Disease Control and Prevention .Public Health Genomics: Genomic Testing. ACCE Model Process for Evaluating Genetic Tests. http://www.cdc.gov/genomics/gtesting/ACCE/index.htm (last access date 4.1.2011)
48 Centers for Disease Control and Prevention .Public Health Genomics: Genomics Translation: Genomic Applications in Practice and Prevention Network (GAPPNet™). http://www.cdc.gov/genomics/translation/GAPPNet/index.htm (last access date 4.1.2011)
49 Evaluation of Genomic Applications in Practice and Prevention (EGAPP). http://www.egappreviews.org/default.htm (last access date 4.1.2011)
50 Working Group: Evidence Reports .Evaluation of Genomic Applications in Practice and Prevention (EGAPP). http://www.egappreviews.org/workingrp/reports.htm (last access date 4.1.2011)
51 The European Medicines Agency .The European Medicines Agency Road Map to 2010: Preparing the Ground for the Future. Executive Summary. http://www.emea.europa.eu/pdfs/general/direct/directory/3416303enF.pdf (last access date 4.1.2011)
52 U.S. Food and Drug Administration .Table of Pharmacogenomic Biomarkers in Drug Labels. http://www.fda.gov/Drugs/ScienceResearch/ResearchAreas/Pharmacogenetics/ucm083378.htm (last access date 4.1.2011)
53 U.S. Food and Drug Administration .For consumers: Important safety-related label update for Ziagen (abacavir sulfate). http://www.fda.gov/ForConsumers/ByAudience/ForPatientAdvocates/HIVandAIDSActivities/ ucm121646.htm (last access date 4.1.2011)
54 U.S. Food and Drug Administration .FDA’s Critical Path Initiative. http:// www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ucm076689.htm (last access date 19.02.2011)
55 U.S: Government Printing Office .Public Law 110-233 – Genetic Information Nondiscrimination Act of 2008. http://www.gpo.gov/fdsys/pkg/PLAW- 110publ233/content-detail.html (last access date 4.1.2011)
56 HuGE Navigator .An integrated, searchable knowledge base of genetic associations and human genome epidemiology. http://www.hugenavigator.net/ (last access date 4.1.2011)
57 GAPP Knowledge Base .An integrated, searchable knowledge base of genomic applications in practice and prevention (GAPP). http://www.hugenavigator.net/GAPPKB/home.do (last access date 4.1.2011)
58 GANI_MED .Greifswald Approach to Individualized Medicine. http://www.medizin.uni-greifswald.de/gani_med/ (last access date 4.1.2011)
59 National Center for Biotechnology Information .Single Nucleotide Polymorphism. http://www.ncbi.nlm.nih.gov/projects/SNP/ (last access date 4.1.2011)
60 Pathway Genomics .Drug Response (Medication). http://www.pathway.com/ more_info/drug_responses (last access date 4.1.2011)
61 Wellcome Trust Sanger Institute .NCI-60 Cancer Cell Line Mutation Data. http://www.sanger.ac.uk/genetics/CGP/NCI60/ (last access date 4.1.2011)
62 Warfarin Dosing. http://www.warfarindosing.org/Source/Home.aspx (last access date 4.1.2011)
63 23andMe .Genetics just got personal. http://www.23andme.com (last access date 4.1.2011)
64 23andMe .Advisory board. http://www.23andme.com/about/advisors/ (last access date 4.1.2011)
65 1000 Genomes .A Deep Catalog of Human Genetic Variation. http://www.1000genomes.org/ (last access date 4.1.2011)
66 Yu W, Gwinn M, Clyne M et al. A navigator for human genome epidemiology. Nat Genet. 2008; 40 124-125
67 Zanger U M, Turpeinen M, Klein K et al. Functional pharmacogenetics/genomics of human cytochromes P 450 involved in drug biotransformation. Anal Bioanal Chem. 2008; 392 1093-1108
68 Zanger U M. Pharmacogenetics - challenges and opportunities ahead. Front Pharmacol. 2010; 1 112 DOI: 10.3389/fphar.2010.00112

Prof. Dr. Matthias Schwab

Dr. Margarete Fischer-Bosch Institut für Klinische Pharmakologie

Auerbachstraße 112

70376 Stuttgart

Phone: ++ 49/7 11/81 01 37 00

Fax: ++ 49/7 11/85 92 95

Email: eMail matthias.schwab@ikp-stuttgart.de